Have Decentralized Clinical Trials Become The New Normal?

By Jerome Armellini, Asia Head of Clinical Development & Operations Strategy, R&D Solutions Asia, IQVIA Asia Pacific

Decentralized trials are evidently gamechangers and are here to stay. They have greatly enhanced the clinical trial arena by bringing patient needs to the fore – from giving them greater access to trial participation, to driving clinical efficiencies and ensuring the drug to market process is ultimately accelerated for them. As the pandemic eases and normalcy returns, it is important for EBPs to engage the right CRO to ensure a smooth transition from either fully traditional clinical trials or DCTs into a hybrid model.